Abstract
Premature fusion of one or more of the cranial sutures (craniosynostosis) in humans causes over 100 skeletal diseases, which occur in 1 of ∼2,500 live births1,2,3. Among them is Apert syndrome, one of the most severe forms of craniosynostosis, primarily caused by missense mutations leading to amino acid changes S252W or P253R in fibroblast growth factor receptor 2 (FGFR2)4,5,6. Here we show that a small hairpin RNA targeting the dominant mutant form of Fgfr2 (Fgfr2S252W) completely prevents Apert-like syndrome in mice. Restoration of normal FGFR2 signaling is manifested by an alteration of the activity of extracellular signal-regulated kinases 1 and 2 (ERK1/2), implicating the gene encoding ERK and the genes downstream of it in disease expressivity. Furthermore, treatment of the mutant mice with U0126, an inhibitor of mitogen-activated protein (MAP) kinase kinase 1 and 2 (MEK1/2) that blocks phosphorylation and activation of ERK1/2, significantly inhibits craniosynostosis. These results illustrate a pathogenic role for ERK activation in craniosynostosis resulting from FGFR2 with the S252W substitution and introduce a new concept of small-molecule inhibitor–mediated prevention and therapy for diseases caused by gain-of-function mutations in the human genome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Katzen, J.T. & McCarthy, J.G. Syndromes involving craniosynostosis and midface hypoplasia. Otolaryngol Clin. North Am. 33, 1257–1284 (2000).
Muenke, M. & Schell, U. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet. 11, 308–313 (1995).
Renier, D., Lajeunie, E., Arnaud, E. & Marchac, D. Management of craniosynostoses. Childs Nerv. Syst. 16, 645–658 (2000).
Ibrahimi, O.A., Chiu, E.S., McCarthy, J.G. & Mohammadi, M. Understanding the molecular basis of Apert syndrome. Plast. Reconstr. Surg. 115, 264–270 (2005).
Moloney, D.M. et al. Exclusive paternal origin of new mutations in Apert syndrome. Nat. Genet. 13, 48–53 (1996).
Park, W.J. et al. Analysis of phenotypic features and FGFR2 mutations in Apert syndrome. Am. J. Hum. Genet. 57, 321–328 (1995).
Coumoul, X. & Deng, C.X. Roles of FGF receptors in mammalian development and congenital diseases. Birth Defects Res. C Embryo Today 69, 286–304 (2003).
Ornitz, D.M. & Itoh, N. Fibroblast growth factors. Genome Biol. 2 REVIEWS3005 (2001) (doi:10.1186/gb-2001-2-3-reviews3005).
Powers, C.J., McLeskey, S.W. & Wellstein, A. Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer 7, 165–197 (2000).
Chen, L. & Deng, C.X. Roles of FGF signaling in skeletal development and human genetic diseases. Front. Biosci. 10, 1961–1976 (2005).
McIntosh, I., Bellus, G.A. & Jab, E.W. The pleiotropic effects of fibroblast growth factor receptors in mammalian development. Cell Struct. Funct. 25, 85–96 (2000).
Chen, L., Li, D., Li, C., Engel, A. & Deng, C.X.A. Ser252Trp substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone 33, 169–178 (2003).
Lakso, M. et al. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc. Natl. Acad. Sci. USA 93, 5860–5865 (1996).
Coumoul, X., Shukla, V., Li, C., Wang, R.H. & Deng, C.X. Conditional knockdown of Fgfr2 in mice using Cre-LoxP induced RNA interference. Nucleic Acids Res. 33, e102 (2005) (doi:10.1093/nar/gni100).
Coumoul, X., Li, W., Wang, R.H. & Deng, C. Inducible suppression of Fgfr2 and Survivin in ES cells using a combination of the RNA interference (RNAi) and the Cre-LoxP system. Nucleic Acids Res. 32, e85 (2004).
Ralph, G.S. et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11, 429–433 (2005).
Chikazu, D. et al. Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase. J. Biol. Chem. 275, 31444–31450 (2000).
Xiao, G., Jiang, D., Gopalakrishnan, R. & Franceschi, R.T. Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. J. Biol. Chem. 277, 36181–36187 (2002).
Chaudhary, L.R. & Avioli, L.V. Activation of extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) by FGF-2 and PDGF-BB in normal human osteoblastic and bone marrow stromal cells: differences in mobility and in-gel renaturation of ERK1 in human, rat, and mouse osteoblastic cells. Biochem. Biophys. Res. Commun. 238, 134–139 (1997).
Spector, J.A. et al. FGF-2 acts through an ERK1/2 intracellular pathway to affect osteoblast differentiation. Plast. Reconstr. Surg. 115, 838–852 (2005).
Kim, H.J. et al. Erk pathway and activator protein 1 play crucial roles in FGF2-stimulated premature cranial suture closure. Dev. Dyn. 227, 335–346 (2003).
Rubinfeld, H. & Seger, R. The ERK cascade: a prototype of MAPK signaling. Mol. Biotechnol. 31, 151–174 (2005).
Cabrita, M.A. & Christofori, G. Sprouty proteins: antagonists of endothelial cell signaling and more. Thromb. Haemost. 90, 586–590 (2003).
Smith, T.G., Sweetman, D., Patterson, M., Keyse, S.M. & Munsterberg, A. Feedback interactions between MKP3 and ERK MAP kinase control scleraxis expression and the specification of rib progenitors in the developing chick somite. Development 132, 1305–1314 (2005).
Furthauer, M., Lin, W., Ang, S.L., Thisse, B. & Thisse, C. Sef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signalling. Nat. Cell Biol. 4, 170–174 (2002).
Favata, M.F. et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623–18632 (1998).
Perlyn, C.A., Morriss-Kay, G., Darvann, T., Tenenbaum, M. & Ornitz, D.M. A model for the pharmacological treatment of Crouzon syndrome. Neurosurgery 59, 210–215 (2006).
Eswarakumar, V.P. et al. Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis. Proc. Natl. Acad. Sci. USA 103, 18603–18608 (2006).
Sui, G. et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99, 5515–5520 (2002).
Yang, X. et al. TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J. Cell Biol. 153, 35–46 (2001).
Acknowledgements
We thank X. Xu, C. Li and L. Cao for critical discussions. We thank T. Fishler, J. De Soto, J. Miller and A. McPherron for critically reading the manuscript. This work was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases (US National Institutes of Health).
Author information
Authors and Affiliations
Contributions
V.S. performed most experiments, X.C. generated the U6-Fgfr2S252W shRNA transgenic mice and performed shRNA-related experiments, R.-H.W. and H.-S.K. participated in RT-PCR and data analysis and C.-X.D. designed the strategy and wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–6, Supplementary Tables 1–3 (PDF 1225 kb)
Rights and permissions
About this article
Cite this article
Shukla, V., Coumoul, X., Wang, RH. et al. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet 39, 1145–1150 (2007). https://doi.org/10.1038/ng2096
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng2096
This article is cited by
-
Septal chondrocyte hypertrophy contributes to midface deformity in a mouse model of Apert syndrome
Scientific Reports (2021)
-
Insights and future directions of potential genetic therapy for Apert syndrome: A systematic review
Gene Therapy (2021)
-
RUNX2-modifying enzymes: therapeutic targets for bone diseases
Experimental & Molecular Medicine (2020)
-
ERK signalling: a master regulator of cell behaviour, life and fate
Nature Reviews Molecular Cell Biology (2020)
-
Nonsyndromic craniosynostosis: novel coding variants
Pediatric Research (2019)